Melanoma/Skin Cancer News

Old age and the development of subsequent primary invasive melanoma are risk factors for death following a melanoma in situ diagnosis, according to a study.

The FDA has approved Avita Medical’s premarket approval supplement for the use of its Recell System for the treatment of full-thickness skin defects, according to a press release.

CHICAGO — Higher tumor mutational burden appeared associated with more favorable real-world OS among a large cohort of patients with various cancer types who used immune checkpoint inhibitor monotherapy.

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.

CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.

CHICAGO — Tumor lymph node dissection likely can be omitted for patients with melanoma who achieve major pathologic response after neoadjuvant immune checkpoint blockade, according to study results presented at ASCO Annual Meeting.

The quality and quantity of ultraviolet B phototherapy sessions for the treatment of atopic dermatitis did not increase the risk of skin cancer development in patients, according to a study.

Understanding the types of gene expression profiling available may help practitioners integrate these tools into their practices, according to a study.

Obtaining RNA samples from suspicious lesions via tape stripping was found to be a valid technique for detecting cutaneous malignant melanoma, according to a study.

Patients with persistent melanoma in situ have shown tumor clearance with imiquimod after surgery, according to a study.